{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Osteoarthritis",
            "NStudiesAvail": 430108,
            "NStudiesFound": 123,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 123,
            "FieldList": [
                  "Acronym",
                  "AgreementOtherDetails",
                  "AgreementPISponsorEmployee",
                  "AgreementRestrictionType",
                  "AgreementRestrictiveAgreement",
                  "ArmGroupDescription",
                  "ArmGroupInterventionName",
                  "ArmGroupLabel",
                  "ArmGroupType",
                  "AvailIPDComment",
                  "AvailIPDId",
                  "AvailIPDType",
                  "AvailIPDURL",
                  "BaselineCategoryTitle",
                  "BaselineClassDenomCountGroupId",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection.",
                              "The patients who are in control group and underwent placebo injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cell",
                              "placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01504464"
                        ]
                  },
                  {
                        "Rank": 2,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Low dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "High dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "No intervention"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Low dose mesenchymal stem cells",
                              "Procedure: Intraarticular injection",
                              "Biological: High dose mesenchymal stem cells",
                              "Procedure: Intraarticular injection"
                        ],
                        "ArmGroupLabel": [
                              "Low dose mesenchymal stem cells",
                              "High dose mesenchymal stem cells",
                              "Control groups"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03383081"
                        ]
                  },
                  {
                        "Rank": 3,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection",
                              "The patients who are in control group and underwent placebo injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cell",
                              "placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03164083"
                        ]
                  },
                  {
                        "Rank": 4,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord mesenchymal stem cells injection is applied for knee OA patients."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05160831"
                        ]
                  },
                  {
                        "Rank": 5,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow mesenchymal stem cells 10 cc by intra articular injection once",
                              "Stromal vascular factor from adipose mesenchymal stem cells 10 cc by intra articular injection once",
                              "Bone marrow and Stromal vascular factor from adipose mesenchymal stem cells 5 cc each one, by intra articular injection once."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow mesenchymal stem cells",
                              "Biological: Adipose Mesenchymal stem cells",
                              "Biological: bone marrow & adipose mesenchymal stem cells injection"
                        ],
                        "ArmGroupLabel": [
                              "bone marrow mesenchymal stem cell",
                              "adipose mesenchymal stem cells",
                              "Bone marrow and Adipose mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04351932"
                        ]
                  },
                  {
                        "Rank": 6,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous bone marrow-derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Hyaluronic Acid",
                              "Biological: Autologous bone marrow-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Hyaluronic acid",
                              "Bone marrow mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01459640"
                        ]
                  },
                  {
                        "Rank": 7,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "patients with ankle joint osteoarthritis"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "stem cell recipient"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01436058"
                        ]
                  },
                  {
                        "Rank": 8,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receiving intra-articular injection of autologous adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous adipose-derived mesenchymal stem cells",
                              "Procedure: abdominal liposuction"
                        ],
                        "ArmGroupLabel": [
                              "Autologous adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03956719"
                        ]
                  },
                  {
                        "Rank": 9,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with hip joint osteoarthritis who underwent cell injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: stem cell injection"
                        ],
                        "ArmGroupLabel": [
                              "hip osteoarthritis"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01499056"
                        ]
                  },
                  {
                        "Rank": 10,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)",
                              "Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)",
                              "Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intra-articular injection of ADMSC",
                              "Biological: Intra-articular injection of ADMSC",
                              "Biological: Intra-articular injection of ADMSC"
                        ],
                        "ArmGroupLabel": [
                              "osteoarthritis of the knee",
                              "osteoarthritis of the hip",
                              "osteoarthritis of the glenohumeral joint"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03869229"
                        ]
                  },
                  {
                        "Rank": 11,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Normal salin injection in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.",
                              "Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: placebo",
                              "Biological: mesenchymal cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "placebo",
                              "mesencymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01873625"
                        ]
                  },
                  {
                        "Rank": 12,
                        "Acronym": [
                              "KDD&MSV"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow collected from patient will be used for mesenchymal stem cells isolation and expansion under GMP conditions at IBGM-Valladolid (MSV). Autologous MSV implanted in knee by articular injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Autologous bone marrow mesenchymal stem cells (MSV)"
                        ],
                        "ArmGroupLabel": [
                              "MSV autologous transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01183728"
                        ]
                  },
                  {
                        "Rank": 13,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Week 1: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis)",
                              "Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin\u00ae, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin\u00ae, Novell Pharmaceutical Laboratories)",
                              "Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis)",
                              "Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin\u00ae, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin\u00ae, Novell Pharmaceutical Laboratories)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Hyaluronic Acid",
                              "Drug: Hyaluronic Acid",
                              "Biological: Umbilical Cord Mesenchymal Stem Cell",
                              "Biological: Recombinant Human Somatropin",
                              "Drug: Hyaluronic Acid",
                              "Biological: Umbilical Cord Mesenchymal Stem Cell",
                              "Drug: Hyaluronic Acid",
                              "Biological: Recombinant Human Somatropin"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Intervention 1",
                              "Intervention 2",
                              "Intervention 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03800810"
                        ]
                  },
                  {
                        "Rank": 14,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receiving intraarticular injection of low dose of mesenchymal stem cells.",
                              "Patients receiving intraarticular injection of high dose of mesenchymal stem cells.",
                              "Patients receiving intraarticular injection of Sodium Hyaluronate"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Low Dose of Mesenchymal stem cell",
                              "Biological: High Dose of Mesenchymal stem cell",
                              "Drug: Sodium Hyaluronate"
                        ],
                        "ArmGroupLabel": [
                              "Low Dose of Mesenchymal stem cell",
                              "High Dose of Mesenchymal stem cell",
                              "Sodium Hyaluronate"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04130100"
                        ]
                  },
                  {
                        "Rank": 15,
                        "Acronym": [
                              "MSV_allo"
                        ],
                        "AgreementOtherDetails": [
                              "The only disclosure restriction on the PI is that the sponsor must review results communications prior to public release."
                        ],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [
                              "OTHER"
                        ],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.",
                              "Intraarticular injection of hyaluronic acid (60 mg)"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Allogenic mesenchymal stromal cells injection",
                              "Drug: Hyaluronic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic mesenchymal stromal cells injection",
                              "Hyaluronic acid (Durolane)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01586312"
                        ]
                  },
                  {
                        "Rank": 16,
                        "Acronym": [
                              "MSCPRPOAK"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 10 ml of Mesenchymal stem cell suspension and 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle",
                              "About 100 ml of venous blood would be drawn with aseptic technique from the antecubital vein with an 18g needle , in order to avoid irritation and trauma to the platelets which are in a resting state. The blood would be collected in a 100 ml paediatric bag with CPDA(citrate phosphate dextrose adenine) as anti coagulant. A leucocyte filter will be also used to filter off the leucocytes. The blood will be then centrifuged for 15 min at 1300 rpm. This separates blood in to RBC( packed red blood cells) and platelet rich plasma. Next the PRP will be passed through a leucocyte filter to obtain leucocyte poor platelet rich plasma. 10 ml of PRP will be dispensed in a sterile syringe. The PRP would be used for injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell suspension",
                              "Biological: PRP",
                              "Biological: PRP"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell, PRP",
                              "platelet rich plasma"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01985633"
                        ]
                  },
                  {
                        "Rank": 17,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal Stem Cells from adipose will be injected.",
                              "Hyaluronic acid will be injectied."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells from adipose",
                              "Biological: Hyaluronic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells from adipose",
                              "hyaluronic acid"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03357575"
                        ]
                  },
                  {
                        "Rank": 18,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intra-articular Wharton Jelly derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of WJMSC in each dose"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton Jelly derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Wharton Jelly mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02963727"
                        ]
                  },
                  {
                        "Rank": 19,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intra Articular injection in Patients with osteoarthritis of knee joint"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Injection"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01207661"
                        ]
                  },
                  {
                        "Rank": 20,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The OA subgroup will be patients aged 18-60 years who have chronic knee pain due to early OA that have not responded to conservative, non-invasive measures such as physical therapy, medications, and activity modification.",
                              "The focal chondral defect subgroup will be patients aged 18-60 years who participate in recreational or professional sports and are symptomatic from a focal chondral defect shown on MRI."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Osteoarthritis",
                              "Cartilage"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03477942"
                        ]
                  },
                  {
                        "Rank": 21,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 1 x 10 E7 cells (3 ml), Frequency: 0,3 weeks.",
                              "Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 2 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.",
                              "Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage:5 x 10 E7 cells (3 ml). Frequency: 0,3 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells low-dose group",
                              "Biological: Mesenchymal stem cells mid-dose group",
                              "Biological: Mesenchymal stem cells high-dose group"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells low-dose group",
                              "Mesenchymal stem cells mid-dose group",
                              "Mesenchymal stem cells high-dose group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01809769"
                        ]
                  },
                  {
                        "Rank": 22,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intraarticular injection of 2\u00d710~7 Umbilical-cord mesenchimal stem cells with plateler Rich Plasma(5ml)",
                              "Intraarticular injection of hyaluronic acid"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical-cord mesenchymal stromal cells (UC-MSCs)",
                              "Other: Hyaluronic acid"
                        ],
                        "ArmGroupLabel": [
                              "Intervention group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03166865"
                        ]
                  },
                  {
                        "Rank": 23,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord tissue-derived mesenchymal stem cells administered into the knee joint once",
                              "Human umbilical cord tissue-derived mesenchymal stem cells administered once per day for 3 consecutive days"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord tissue-derived mesenchymal stem cells",
                              "Biological: Human umbilical cord tissue-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Intra-articular knee injection of UC-MSC",
                              "IV injection of UC-MSC"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02237846"
                        ]
                  },
                  {
                        "Rank": 24,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intra-articular adipose tissue derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of ATMSC in each dose"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adipose tissue derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "adipose tissue mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02966951"
                        ]
                  },
                  {
                        "Rank": 25,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three intra-articular injections of ADMSCs at the dose of 8~10x10^6 cells/injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Adipose-Derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "ADMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02544802"
                        ]
                  },
                  {
                        "Rank": 26,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three intra-articular injections in total and autologous bone marrow-derived mesenchymal stem cells (BMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.",
                              "Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Auotologous BMSCs plus autologous PRP",
                              "Biological: Auotologous PRP"
                        ],
                        "ArmGroupLabel": [
                              "BMSCs plus PRP group",
                              "PRP group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03969680"
                        ]
                  },
                  {
                        "Rank": 27,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intraarticular dose of allogeneic MSCs suspended in 2-4ml Plasmalyte A followed by 2 ml of Hyaluronan",
                              "Single intraarticular dose of 2ml Plasmalyte"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Ex- vivo cultured adult allogeneic MSCs",
                              "Biological: Plasmalyte-A"
                        ],
                        "ArmGroupLabel": [
                              "Ex- vivo cultured adult allogeneic MSCs",
                              "Plasmalyte-A"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01453738"
                        ]
                  },
                  {
                        "Rank": 28,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intraarticular injection of WJMSC",
                              "Intraarticular injection of WJMSC",
                              "Intraarticular injection of WJMSC"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intraarticular injection of WJMSC",
                              "Biological: Intraarticular injection of WJMSC",
                              "Biological: Intraarticular injection of WJMSC"
                        ],
                        "ArmGroupLabel": [
                              "osteoarthritis of the knee",
                              "osteoarthritis of the hip",
                              "osteoarthritis of the glenohumeral joint"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03866330"
                        ]
                  },
                  {
                        "Rank": 29,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intraarticular injection of Hyaluronic acid (Hyal One)",
                              "Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million Bone marrow mesenchimal stem cells",
                              "Single intraarticular injection of Hyaluronic acid (Hyal One) 100 million Bone marrow mesenchimal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Hyaluronic acid",
                              "Drug: Hyaluronic acid",
                              "Biological: 10 million Bone marrow mesenchimal stem cells",
                              "Drug: Hyaluronic acid",
                              "Biological: 100 million Bone marrow mesenchimal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Hialuronic acid",
                              "Hyaluronic acid and MSC 10",
                              "Hyaluronic acid AND MSC 100"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02123368"
                        ]
                  },
                  {
                        "Rank": 30,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.",
                              "Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.",
                              "Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human allogeneic mesenchymal bone marrow derived stem cells",
                              "Biological: Human allogeneic mesenchymal bone marrow derived stem cells",
                              "Biological: Human allogeneic mesenchymal bone marrow derived stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2",
                              "Group 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03602872"
                        ]
                  },
                  {
                        "Rank": 31,
                        "Acronym": [
                              "CMM-PRGF/ART"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Platelet Rich plasma (PRGF) 3 intraarticular onjections sepataded by 7 days.",
                              "Single intraarticular injection of 100 million Bone marrow mesenchimal stem cells and three intraarticular injections of plateler Rich Plasma (PRGF) separatede by 7 days."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Platelet Rich plasma (PRGF)",
                              "Biological: 100 million Bone marrow mesenchimal stem cells",
                              "Biological: Platelet Rich plasma (PRGF)"
                        ],
                        "ArmGroupLabel": [
                              "Platelet Rich Plasma (PRGF)",
                              "BMMSC with Platelet Rich Plasma (PRGF)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02365142"
                        ]
                  },
                  {
                        "Rank": 32,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three intra-articular injections in total and autologous adipose-derived mesenchymal stem cells (AMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.",
                              "Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Auotologous AMSCs plus autologous PRP",
                              "Biological: Auotologous PRP"
                        ],
                        "ArmGroupLabel": [
                              "AMSCs plus PRP group",
                              "PRP group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04212728"
                        ]
                  },
                  {
                        "Rank": 33,
                        "Acronym": [
                              "OA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "After arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.",
                              "After arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection.",
                              "Without arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.",
                              "Without arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome",
                              "Biological: Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome",
                              "Biological: Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome",
                              "Biological: Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome"
                        ],
                        "ArmGroupLabel": [
                              "Arthroscopy + Booster",
                              "Arthroscopy + Pre-Conditioning",
                              "Non Arthroscopy + Booster",
                              "Non Arthroscopy + Pre-Conditioning"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04314661"
                        ]
                  },
                  {
                        "Rank": 34,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Experimental Group 1: Three intra-articular injection of allogeneic P-MMSCs up to 2\u2022107cells (target dose up to 6\u2022107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients",
                              "Experimental Group 2: Three intra-articular injection of autologous BM-MMSCs up to 2\u2022107cells (target dose up to 6\u2022107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients",
                              "Three intra-articular injection of 20 mg Hyaluronic Acid - 15 patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Placenta-derived MMSCs",
                              "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe",
                              "Biological: Bone marrow-derived MMSCs",
                              "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe",
                              "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe"
                        ],
                        "ArmGroupLabel": [
                              "Hyaluronic Acid (HA) + P-MMSCs",
                              "Hyaluronic Acid (HA) + BM-MMSCs",
                              "Hyaluronic Acid (HA)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04453111"
                        ]
                  },
                  {
                        "Rank": 35,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intraarticular dose of allogeneic MSCs",
                              "Single intraarticular dose of 2ml Plasmalyte"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Ex- vivo cultured adult allogeneic MSCs",
                              "Biological: Plasmalyte-A"
                        ],
                        "ArmGroupLabel": [
                              "Ex- vivo cultured adult allogeneic MSCs",
                              "Plasmalyte-A"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01448434"
                        ]
                  },
                  {
                        "Rank": 36,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Inject mesenchymal stem cells from umbilical cord. The patients will be followed up at 1, 2, 3, and 6 months after the injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: mesenchymal stem cells from umbilical cord"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03358654"
                        ]
                  },
                  {
                        "Rank": 37,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee.\n\nThe treatment will be carried out after the patient has received a blood test and clinically evaluated at T0.\n\nT0: Beginning of the study, blood test and bone marrow aspiration. T30: Intra-articular injection of MSCs T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)",
                              "The patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.) The hyaluronic acid will be purchased for the patient from the manufacturer or from the pharmacy of the hospital.The intra-articular injection will be carried out after the patient has received a clinical evaluation at T0.\n\nT0: Beginning of the study T30: Intra-articular injection of Synvisc-One (HA) T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells Treatment (MSCs)",
                              "Drug: Hyaluronic acid (HA)"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Stem Cells Treatment (MSCs)",
                              "Hyaluronic acid (HA)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04326985"
                        ]
                  },
                  {
                        "Rank": 38,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01159899"
                        ]
                  },
                  {
                        "Rank": 39,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion and intraarticular injection (total dose of 100 million cells)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05147675"
                        ]
                  },
                  {
                        "Rank": 40,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection of bone marrow aspirate concentrate (BMAC) withdrawn from a bone near the hip into the knee joint (intra-articular) immediately followed by an injection of platelet-rich plasma (PRP) into the knee joint.",
                              "Gel-One\u00ae is an hyaluronate gel used in the treatment of knee osteoarthritis by injection into the knee joint (intra-articular)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BMAC injection",
                              "Biological: PRP injection",
                              "Device: Gel-One\u00ae hyaluronate injection"
                        ],
                        "ArmGroupLabel": [
                              "BMAC injection and PRP injection",
                              "Gel-One\u00ae hyaluronate injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002"
                        ],
                        "NCTId": [
                              "NCT02958267"
                        ]
                  },
                  {
                        "Rank": 41,
                        "Acronym": [
                              "AdMSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.",
                              "Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion",
                              "50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.",
                              "Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion",
                              "50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.",
                              "Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Phase 2 Arm 1 - OA Knee",
                              "Phase 2 Arm 2 OA Knee",
                              "Phase 2 Arm 3 - OA Hip",
                              "Phase 2 Arm 4 - OA Hip",
                              "Phase 2 Arm 5 - OA Shoulder",
                              "Phase 2 Arm 6 - OA Shoulder"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Experimental",
                              "Active Comparator",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04448106"
                        ]
                  },
                  {
                        "Rank": 42,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow aspiration, Autologous bone marrow-derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Bone marrow aspiration"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01895413"
                        ]
                  },
                  {
                        "Rank": 43,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Trophic factors from umbilical cord mesenchymal stem cells administered intra-articularly.",
                              "Trophic factors from umbilical cord mesenchymal stem cells administered subcutaneously once per week for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Trophic factors from umbilical cord mesenchymal stem cells",
                              "Biological: Trophic factors from umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Intra-articular knee injection of MTF",
                              "Subcutaneous injection of MTF"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02003131"
                        ]
                  },
                  {
                        "Rank": 44,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Triamcinolone acetonide (10mg / mL) via intra-articular, 5 cc, one dose (zero time).",
                              "CELLISTEM-OA via intra-articular, doses of 2 x 106 mesenchymal stem cells in 5cc of saline solution, one dose (zero time)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Triamcinolone acetonide",
                              "Biological: CELLISTEM-OA"
                        ],
                        "ArmGroupLabel": [
                              "Group 1 (control-Triamcinolone acetonide)",
                              "Group 2 (experimental- CELLISTEM-OA)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04863183"
                        ]
                  },
                  {
                        "Rank": 45,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01300598"
                        ]
                  },
                  {
                        "Rank": 46,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will undergo a bone marrow aspirate procedure. Participants will receive a single intra-articular injection of NGRM-001 on treatment day.",
                              "Participants will undergo a bone marrow aspirate procedure. Participants will receive a single subchondral injection of NGRM-001 on treatment day.",
                              "Participants will undergo a bone marrow aspirate procedure. Participants will receive a single combined intra-articular and subchondral injection of NGRM-001 on treatment day.",
                              "Subjects in the corticosteroid group will undergo a mock bone marrow aspirate procedure. Participants will receive a single intra-articular injection of corticosteroid on treatment day."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone Marrow Derived MSCs",
                              "Device: Bone Marrow Aspirate",
                              "Biological: Bone Marrow Derived MSCs",
                              "Device: Bone Marrow Aspirate",
                              "Biological: Bone Marrow Derived MSCs",
                              "Device: Bone Marrow Aspirate",
                              "Drug: Corticosteroid",
                              "Device: Bone Marrow Aspirate"
                        ],
                        "ArmGroupLabel": [
                              "Intra-articular injection with Bone Marrow Derived Mesenchymal Stem Cells (MSCs)",
                              "Subchondral injection with Bone Marrow Derived MSCs",
                              "Combined Intra-articular and Subchondral injection with Bone Marrow Derived MSCs",
                              "Corticosteroid injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05288725"
                        ]
                  },
                  {
                        "Rank": 47,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02291926"
                        ]
                  },
                  {
                        "Rank": 48,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose tissue derived Mesenchymal Stem Cells(AdMSC)",
                              "Normal Saline with Autologous Serum"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: JointStem",
                              "Other: Placebo Control"
                        ],
                        "ArmGroupLabel": [
                              "JointStem",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04368806"
                        ]
                  },
                  {
                        "Rank": 49,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00850187"
                        ]
                  },
                  {
                        "Rank": 50,
                        "Acronym": [
                              "MILES"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants randomized to this arm will undergo bone marrow aspiration and then will be further randomized to receive a standard orthobiologic injection into the knee joint of autologous bone marrow concentrate (BMAC).",
                              "Participants randomized to this arm will undergo small volume lipoplasty, and then will be further randomized to receive an injection into the knee joint of adipose-derived stromal vascular fraction (SVF).",
                              "Participants randomized to this arm will receive an injection into the knee joint of cryopreserved doses of umbilical cord tissue MSCs.",
                              "Participants randomized to the bone marrow derived MSC, adipose-derived MSC, or umbilical cord tissue MSC study arms will be further randomized within the arm in a 3:1 ratio to receive either MSCs derived from the study arm of the initial randomization or a corticosteroid (CS) injection. Participants randomized to the control group will receive an injection of corticosteroid into the knee joint."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone Marrow Derived MSCs",
                              "Biological: Adipose-derived MSCs",
                              "Biological: Umbilical Cord Tissue (UCT) MSCs",
                              "Drug: Corticosteroid injection"
                        ],
                        "ArmGroupLabel": [
                              "Bone Marrow Derived MSCs",
                              "Adipose-derived MSCs",
                              "Umbilical Cord Tissue (UCT) MSCs",
                              "Corticosteroid Injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03818737"
                        ]
                  },
                  {
                        "Rank": 51,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human Umbilical Cord Derived-Mesenchymal Stem Cells. Subjects will receive a single-dose intra-articular (IA) injection of UMC119-06-05 followed by an IA injection of hyaluronic acid."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UMC119-06-05",
                              "Device: Hyaluronic acid"
                        ],
                        "ArmGroupLabel": [
                              "UMC119-06-05"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04893174"
                        ]
                  },
                  {
                        "Rank": 52,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "50 participants will receive the investigational drug (Chondrogen and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.",
                              "50 participants will receive the placebo (Saline and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Chondrogen",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Active Participant of Phase 2B Clinical Study Chondrogen",
                              "Placebo Participant of Phase 2B Clinical Study Chondrogen"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04520945"
                        ]
                  },
                  {
                        "Rank": 53,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "TENS , Open chain knee flexion and extension, Calf stretch , Quad set",
                              "MET ( isometric contraction with 6-10 sec )"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: CONVENTIONAL PHYSICAL THERAPY",
                              "Other: MUSCLE ENERGY TECHNIQUE"
                        ],
                        "ArmGroupLabel": [
                              "CONVENTIONAL PHYSICAL THERAPY",
                              "MUSCLE ENERGY TECHNIQUE"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05349565"
                        ]
                  },
                  {
                        "Rank": 54,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants who self-select into the Group 1 (Immediate Treatment) will be scheduled to undergo the HAM and HUMCWJ injections to the OA affected knee at the same visit.",
                              "Participants who self-select into Group 2 will choose to delay their HAM and HUMCWJ injection to the OA affected knee for at least 3 months or choose not to have the injections at all. Participants will be asked to keep track of pain management and therapy throughout the 3 months."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: HAM and HUMCWJ Injections"
                        ],
                        "ArmGroupLabel": [
                              "HAM and HUMCWJ Injections (Group 1)",
                              "Control (Group 2)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03337243"
                        ]
                  },
                  {
                        "Rank": 55,
                        "Acronym": [
                              "MSC-OA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intraarticular injection of Catholic MASTER cell, 1 time, 1 x 10^8 cells/DMEM 5cc, into knee joint of patients with osteoarthritis",
                              "Intraarticular injection of saline, 1 time, 5cc, into knee joint of patients with osteoarthritis"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Catholic MASTER cell",
                              "Other: Saline"
                        ],
                        "ArmGroupLabel": [
                              "MASTER cell",
                              "Saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04240873"
                        ]
                  },
                  {
                        "Rank": 56,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will be IA injected at the target knee with 3 mL of Chondrochymal\u00ae containing 5.0 x 107 BM-MSCs in lactated Ringer's solution at Day 1.",
                              "Hya-Joint Plus Synovial Fluid Supplement containing 60 mg/3 mL of hyaluronic acid will be IA administrated into the subject's target knee at Day 1."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Bone marrow mesenchymal stem cells",
                              "Drug: hyaluronic acid"
                        ],
                        "ArmGroupLabel": [
                              "Chondrochymal\u00ae group",
                              "Hya-Joint Plus Synovial Fluid Supplement"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05027581"
                        ]
                  },
                  {
                        "Rank": 57,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "At this stage, 3 patients with knee OA will be treated by the cell products of this dose.",
                              "At this stage, 3 patients with knee OA will be treated by the cell products of this dose.",
                              "At this stage, 3 patients with knee OA will be treated by the cell products of this dose."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Chondrochymal\u00ae",
                              "Biological: Chondrochymal\u00ae",
                              "Biological: Chondrochymal\u00ae"
                        ],
                        "ArmGroupLabel": [
                              "Chondrochymal\u00ae 1 x 10^7 cells",
                              "Chondrochymal\u00ae 5 x 10^7 cells",
                              "Chondrochymal\u00ae 10 x 10^7 cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03589287"
                        ]
                  },
                  {
                        "Rank": 58,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants currently scheduled to undergo a bone marrow aspirate concentration (BMAC) procedure will be randomized to unilateral procurement of bone marrow.",
                              "Participants currently scheduled to undergo a bone marrow aspirate concentration (BMAC) procedure will be randomized to bilateral procurement of bone marrow."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Unilateral Bone Marrow Procurement",
                              "Procedure: Bilateral Bone Marrow Procurement"
                        ],
                        "ArmGroupLabel": [
                              "Unilateral Procurement of Bone Marrow",
                              "Bilateral Bone Marrow Procurement"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03014037"
                        ]
                  },
                  {
                        "Rank": 59,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose Tissue derived MSCs",
                              "saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: JOINTSTEM",
                              "Drug: saline"
                        ],
                        "ArmGroupLabel": [
                              "JOINTSTEM",
                              "saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03990805"
                        ]
                  },
                  {
                        "Rank": 60,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) along with removal of the calcified cartilage layer. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.",
                              "This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) but with retention of the calcified cartilage cap. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: arthroscopy of the affected knee/ Bone Marrow Concentrate Injection",
                              "Procedure: arthroscopy of the affected knee/ Bone Marrow Concentrate Injection"
                        ],
                        "ArmGroupLabel": [
                              "arthroscopy with removal of calcified cartilage",
                              "arthroscopy without removal of calcified cartilage"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03648463"
                        ]
                  },
                  {
                        "Rank": 61,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical Cord Mesenchymal stem cells (UCMSC) expanded and treated for 1-2 weeks. Then administer 5x10^6 of UCMSC per cm^2 of the cartilage defect.",
                              "Administer hyaluronic acid (30 mg) in a single injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord mesenchymal stem cells",
                              "Device: Hyaluronic acid"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell treatment",
                              "Hyaluronic acid treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02776943"
                        ]
                  },
                  {
                        "Rank": 62,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three groups of patients were enrolled in this study. Every group includes three patients. The three groups of patients were treated with high, medium and low dose of cytokine.The low-dose is 1 \u00d7 10^7cells / 3mL",
                              "the medium-dose is 5 \u00d7 10^7cells / 3mL",
                              "the high dose is 1 \u00d7 10^8cells / 3mL"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: mesenchymal stem cells",
                              "Drug: mesenchymal stem cells",
                              "Drug: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "low dose of mesenchymal stem cells",
                              "medium dose of mesenchymal stem cells",
                              "high dose of mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03357770"
                        ]
                  },
                  {
                        "Rank": 63,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Clinical case series"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Bone Marrow Aspiration",
                              "Procedure: Bone marrow mesenchymal stem cell implantation"
                        ],
                        "ArmGroupLabel": [
                              "Single"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00891501"
                        ]
                  },
                  {
                        "Rank": 64,
                        "Acronym": [
                              "ARTHROSTEM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Blood, bone marrow and Hoffa's fat pad samplings during surgical intervention"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: arthroplasty"
                        ],
                        "ArmGroupLabel": [
                              "Surgical intervention"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01879046"
                        ]
                  },
                  {
                        "Rank": 65,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml, 1 time injection(at 1week after high tibial osteotomy)",
                              "No treatment (after high tibial osteotomy)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose Tissue derived MSCs",
                              "No treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03000712"
                        ]
                  },
                  {
                        "Rank": 66,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: Jointstem"
                        ],
                        "ArmGroupLabel": [
                              "Long Term Follow-up after Jointstem Transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03509025"
                        ]
                  },
                  {
                        "Rank": 67,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intra-articular injection of XSTEM-OA"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: XSTEM-OA"
                        ],
                        "ArmGroupLabel": [
                              "XSTEM-OA"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05344157"
                        ]
                  },
                  {
                        "Rank": 68,
                        "Acronym": [
                              "ASC-OA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04223622"
                        ]
                  },
                  {
                        "Rank": 69,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive 25 x 10^6 of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) with standard treatment.",
                              "Patients will undergo marrow cellution surgical procedure."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)",
                              "Procedure: Marrow cellution"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)",
                              "Marrow cellution (standard treatment)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05016011"
                        ]
                  },
                  {
                        "Rank": 70,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)",
                              "A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10^7 cells/2mL) ( 2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)",
                              "A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: SMUP-IA-01(low-dose)",
                              "Biological: SMUP-IA-01(mid-dose)",
                              "Biological: SMUP-IA-01(high-dose)"
                        ],
                        "ArmGroupLabel": [
                              "SMUP-IA-01(low-dose)",
                              "SMUP-IA-01(mid-dose)",
                              "SMUP-IA-01(high-dose)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04037345"
                        ]
                  },
                  {
                        "Rank": 71,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.",
                              "The control group received intra-articular injection of sodium hyaluronate one month after operation."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Autologous Adipose-derived Mesenchymal Stem Cell Gel",
                              "Procedure: Extraction of abdominal fat",
                              "Drug: Sodium Hyaluronate"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose-derived Mesenchymal Stem Cell Gel",
                              "sodium hyaluronate"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03955497"
                        ]
                  },
                  {
                        "Rank": 72,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Investigational Product - 4.0\u00d710^6 cells/2 mL of SMUP-IA-01 (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)",
                              "Investigational Product - 1.0\u00d710^7 cells/2 mL of SMUP-IA-01 (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)",
                              "Investigational Product - 2 ml of 1% sodium hyaluronate (2 ml of sodium chloride injection is administered before administration of 1% sodium hyaluronate)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: SMUP-IA-01(low dose)",
                              "Biological: SMUP-IA-01(mid dose)",
                              "Drug: Active Control Group Sodium chloride"
                        ],
                        "ArmGroupLabel": [
                              "Study Group 1: SMUP-IA-01 (low dose)",
                              "Study Group 2:SMUP-IA-01 (mid dose)",
                              "Active Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05182034"
                        ]
                  },
                  {
                        "Rank": 73,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Mesenchymal Stem Cells primed prior to intra articular injection into knees of patients with advanced articular cartilage injury",
                              "Autologous Mesenchymal Stem Cells primed prior to intra articular injection with platelet lysate into knees of patients with advanced articular cartilage injury"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "mesenchymal cells&platelet lysate"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02118519"
                        ]
                  },
                  {
                        "Rank": 74,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "autologous adipose tissue derived mesenchymal stem cells (AdMSC)",
                              "hyaluronic acid"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: JointStem",
                              "Drug: Synvisc-One"
                        ],
                        "ArmGroupLabel": [
                              "JointStem",
                              "Synvisc-One"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02674399"
                        ]
                  },
                  {
                        "Rank": 75,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "GXCPC1 contains 6.7\u00d710^6 or 4\u00d710^7 allogeneic adipose-derived stem cells (ADSCs) in 3 mL",
                              "Hya Joint Plus synovial fluid supplement 3mL"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: GXCPC1",
                              "Device: HA"
                        ],
                        "ArmGroupLabel": [
                              "GXCPC1",
                              "hyaluronic acid"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03943576"
                        ]
                  },
                  {
                        "Rank": 76,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)",
                              "A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)",
                              "A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: SMUP-IA-01(low-dose)",
                              "Biological: SMUP-IA-01(mid-dose)",
                              "Biological: SMUP-IA-01(high-dose)"
                        ],
                        "ArmGroupLabel": [
                              "SMUP-IA-01(low-dose)",
                              "SMUP-IA-01(mid-dose)",
                              "SMUP-IA-01(high-dose)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04339504"
                        ]
                  },
                  {
                        "Rank": 77,
                        "Acronym": [
                              "BioMiStem-CT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with osteoarthritis of knee, suffering also with type 2 diabetes and obesity (BMI > 30) will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)",
                              "The patients with osteoarthritis of knee, suffering also with type 2 diabetes and obesity (BMI > 30) will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)",
                              "The patients with osteoarthritis of knee, suffering also with obesity (BMI > 30), but with no type 2 diabetes will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)",
                              "The patients with osteoarthritis of knee, suffering also with obesity (BMI > 30), but with no type 2 diabetes will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)",
                              "The patients with osteoarthritis of knee, with no obesity (BMI < 30) nor type 2 diabetes will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)",
                              "The patients with osteoarthritis of knee, with no obesity (BMI < 30) nor type 2 diabetes will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MesoCellA-Ortho administration",
                              "Drug: HA administration",
                              "Drug: MesoCellA-Ortho administration",
                              "Drug: HA administration",
                              "Drug: MesoCellA-Ortho administration",
                              "Drug: HA administration"
                        ],
                        "ArmGroupLabel": [
                              "MesoCellA-Ortho - treated Patients with type 2 diabetes and with obesity",
                              "Control Patients with type 2 diabetes and obesity",
                              "MesoCellA-Ortho - treated Patients without type 2 diabetes and with obesity",
                              "Control Patients without type 2 diabetes and with obesity",
                              "MesoCellA-Ortho - treated Patients without type 2 diabetes and without obesity",
                              "Control Patients without type 2 diabetes and without obesity"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Experimental",
                              "Active Comparator",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05081921"
                        ]
                  },
                  {
                        "Rank": 78,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with Osteoarthritis A total of 140 patients ( May 2016 to june 2020) were treated with intra articular adipose derived stromal cells (ADSC)) also known as Stromal vascualr fraction administration"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose tissue derived stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Experimental"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05484856"
                        ]
                  },
                  {
                        "Rank": 79,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Long Term Follow-up after Jointstem Transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: JOINTSTEM"
                        ],
                        "ArmGroupLabel": [
                              "JOINTSTEM"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04427930"
                        ]
                  },
                  {
                        "Rank": 80,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Placenta Derived Mesenchymal Stem Cell administered into the knee joint once",
                              "Sodium hyaluronate administered into the knee joint once"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Placenta Derived Mesenchymal Stem Cell",
                              "Drug: Sodium Hyaluronate"
                        ],
                        "ArmGroupLabel": [
                              "Placenta Derived Mesenchymal Stem Cell",
                              "sodium hyaluronate"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03028428"
                        ]
                  },
                  {
                        "Rank": 81,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: JOINTSTEM"
                        ],
                        "ArmGroupLabel": [
                              "Long Term Follow-up after Jointstem Transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04825730"
                        ]
                  },
                  {
                        "Rank": 82,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cells plus standard conservative care.",
                              "Standard Conventional Treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adipose Tissue derived Total-Stromal-Cells (TOST)"
                        ],
                        "ArmGroupLabel": [
                              "Adipose Tissue derived Total-Stromal-Cells (TOST)",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05280002"
                        ]
                  },
                  {
                        "Rank": 83,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Approximately 5mL of intraarticular PRP once at baseline",
                              "Approximately 5mL of intraarticular normal saline once at baseline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Platelet Rich Plasma",
                              "Other: Normal Saline"
                        ],
                        "ArmGroupLabel": [
                              "Platelet Rich Plasma",
                              "Normal Saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02468492"
                        ]
                  },
                  {
                        "Rank": 84,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with post collapse osteonecrosis.",
                              "This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with pre-collapse osteonecrosis.",
                              "This control group will be selected in patients undergoing hip arthroscopy for femoral/acetabular impingement."
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "Collapse ON group",
                              "Pre-collapse group",
                              "FAI group"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02941666"
                        ]
                  },
                  {
                        "Rank": 85,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in the test group received autologous peripheral blood mesenchymal stem cell therapy",
                              "Patients in the control group 1 received microfracture surgical treatment",
                              "Patients in the control group 2 received microfracture combined with surgical treatment of collagen membrane",
                              "Patients in the control group 3 received autologous osteochondral transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: autologous peripheral blood mesenchymal stem cell",
                              "Procedure: Microfracture",
                              "Combination Product: Microfracture + collagen membrane",
                              "Procedure: Autologous osteochondral transplantation"
                        ],
                        "ArmGroupLabel": [
                              "test group",
                              "control group 1",
                              "control group 2",
                              "control group 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04953572"
                        ]
                  },
                  {
                        "Rank": 86,
                        "Acronym": [
                              "BMAC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the autologous bone marrow aspirate concentrate. The contralateral knee will be injected with only sterile saline for placebo.",
                              "Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the bone marrow concentrate. The contralateral knee will be injected with only sterile saline for placebo."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous Bone Marrow Aspirate Concentrate",
                              "Drug: Sterile saline"
                        ],
                        "ArmGroupLabel": [
                              "Autologous bone marrow concentrate",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01931007"
                        ]
                  },
                  {
                        "Rank": 87,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients who are randomized to the placebo group will receive an injection of 7cc of sterile saline in the affected knee.",
                              "Patients who are randomized to the corticosteroid group will receive an injection of 2cc (80mg) of triamcinalone acetonide injectable suspension mixed with 5 cc of 1% plain lidocaine for a total of 7cc of fluid injected in the affected knee.",
                              "Patients who are randomized to the Lipogems treatment group will undergo a lipoaspiration from their abdomen and autologous injection of the harvested adipocytes into their knee. It is standard to harvest three to four times more adipose tissue than is planned to be injected to account for tissue processing by the Lipogems device. The investigators plan to inject 7cc of autologous adipose tissue. Thus, the investigators will harvest between 25 and 30 cc of adipose tissue from each patient. The tissue will be processed immediately and 7cc will be injected. Any remaining adipose tissue will be disposed of immediately in biohazardous waste."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Saline",
                              "Drug: Corticosteroid injection",
                              "Device: Microfragmented Adipose Tissue (Lipogems)"
                        ],
                        "ArmGroupLabel": [
                              "Placebo Injection",
                              "Corticosteroid Injection",
                              "Lipogems Injection"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03379168"
                        ]
                  },
                  {
                        "Rank": 88,
                        "Acronym": [
                              "MarrowMule"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone Marrow concentrate will be injected intra-articularly and at the bone-cartilage interface both in the tibia and femur of patients affected by unicompartmental knee osteoarthritis"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Subchondral and intra-articular injection of BMC"
                        ],
                        "ArmGroupLabel": [
                              "Bone Marrow Concentrate"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03790189"
                        ]
                  },
                  {
                        "Rank": 89,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose Tissue derived MSCs",
                              "Sodium chloride"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: JOINTSTEM",
                              "Drug: Saline solution"
                        ],
                        "ArmGroupLabel": [
                              "Jointstem",
                              "Saline solution"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02658344"
                        ]
                  },
                  {
                        "Rank": 90,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The cases assigned to this group will be injected intra-articularly with Lipogems\u00ae. The patients will undergo harvesting of their own adipose tissue for aMAT then this aMAT will be injected intra-articularly in the knee. It will be administered once at the baseline visit of the study.",
                              "The cases assigned to this group will be injected intra-articularly in the knee with corticosteroids. No extra preparation of any type is necessary in this case. It will be administered once at the baseline visit of the study."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Microfragmented Adipose Tissue Transplant",
                              "Drug: Corticosteroid injection"
                        ],
                        "ArmGroupLabel": [
                              "Lipogems",
                              "Steroid"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04230902"
                        ]
                  },
                  {
                        "Rank": 91,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Stem cells therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03308006"
                        ]
                  },
                  {
                        "Rank": 92,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single dose of 500\u3395/\u33a0 of cartilage defect"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cartistem",
                              "Procedure: Microfracture treatment"
                        ],
                        "ArmGroupLabel": [
                              "Cartistem",
                              "Microfracture treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01041001"
                        ]
                  },
                  {
                        "Rank": 93,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose Tissue derived MSCs",
                              "saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: JOINTSTEM",
                              "Drug: Saline"
                        ],
                        "ArmGroupLabel": [
                              "JOINTSTEM",
                              "Saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04821102"
                        ]
                  },
                  {
                        "Rank": 94,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intra-articular injection of CB-MNCs (cell count 1\u00d7108 cells/time) was performed once every 1 week for a total of 3 times.",
                              "Intra-articular injection of normal saline was performed once every 1 week for a total of 3 times."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Cord Blood Mononuclear Cells (UCB-MNCs)",
                              "Other: normal saline"
                        ],
                        "ArmGroupLabel": [
                              "stem cell treating group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05000593"
                        ]
                  },
                  {
                        "Rank": 95,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Osteoarthritic Knee of the patients who will be treated wth high tibial osteotomy and implantation of allogenic human umbilical cord blood-derived stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: umbilical cord blood stem cell implantation for osteoarthritis treatment"
                        ],
                        "ArmGroupLabel": [
                              "Osteoarthritic knee patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04234412"
                        ]
                  },
                  {
                        "Rank": 96,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical-cord mesenchymal stromal cells (UC-MSCs)\n\nAllogeneic UC-MSCs 20 x 10e6 diluted on 3 mL of saline solution + 5% of Plasma AB\n\nArm 2a: single infusion group. UC-MSCs at 0 month\n\nArm 2b: double infusion group. UC-MSCs at 0 and 6 months",
                              "Drug: Hyaluronic Acid 3 mL of HA intra-articular injection at baseline and 6 months"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical-cord mesenchymal stromal cells",
                              "Drug: Hyaluronic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical-cord mesenchymal stromal cells",
                              "Hyaluronic Acid (HA)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02580695"
                        ]
                  },
                  {
                        "Rank": 97,
                        "Acronym": [
                              "BMAC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow aspirate concentrate (BMAC) will be administered via injection to the knee of interest on day 14 of the study.\n\nBone marrow aspiration will be concentrated using the Angel System."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone Marrow Aspirate Concentrate",
                              "Device: Angel Concentrated Platelet Rich Plasma (cPRP) System"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow aspiration concentrate using the Angel System"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04716803"
                        ]
                  },
                  {
                        "Rank": 98,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with osteoarthritis who underwent PRP injection.",
                              "The patients with osteoarthritis who underwent Normal Saline injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: PRP injection",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "platelet reach plasma",
                              "placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01926327"
                        ]
                  },
                  {
                        "Rank": 99,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Device: Lipogems"
                        ],
                        "ArmGroupLabel": [
                              "injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03788265"
                        ]
                  },
                  {
                        "Rank": 100,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04604288"
                        ]
                  },
                  {
                        "Rank": 101,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "20 participants with symptomatic knee osteoarthritis and ultrasonography defined effusion-synovitis will take natural Senolytic agents.\n\nThe senolytic agents act by Hit-and-run strategy therefore, intermittent dosing regimens will be applied. 1250 mg/day quercetin + 1000mg/day Fisetin for 3 consecutive days every 3 weeks.over 12 weeks",
                              "20 participants with symptomatic knee osteoarthritis and ultrasonography-defined effusion-synovitis will take Quercetin 1250 mg + Fisetin 1000 mg for 3 consecutive days followed by 100mg/day Glycyrrhizin for one week every 3 weeks over 12 weeks .",
                              "Placebo controlled group"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Quercetin Cap/Tab ,Fisetin Cap/Tab",
                              "Drug: Quercetin Cap/Tab,Fisetin Cap/tab,Glycyrrhizin capsules",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "(Quercetin +Fisetin)",
                              "Quercetin +Fisetin +Glycyrrhizin)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05276895"
                        ]
                  },
                  {
                        "Rank": 102,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "0.24mJ/mm2\uff0c1600 shots over 8 assigned sites of single knee with jelly between applicator pad (20) and handpiece\nPhysical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks",
                              "0.24mJ/mm2\uff0c1600 shots over 8 assigned sites of single knee without jelly between applicator pad (20) and handpiece\nPhysical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks"
                        ],
                        "ArmGroupInterventionName": [
                              "Device: shockwave therapy",
                              "Other: PT",
                              "Other: PT",
                              "Other: placebo"
                        ],
                        "ArmGroupLabel": [
                              "shockwave therapy",
                              "placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03048773"
                        ]
                  },
                  {
                        "Rank": 103,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow that is aspirated then concentrated using a device.",
                              "Triamcinolone is a corticosteroid."
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: Aspire Needle + Emcyte PureBMC",
                              "Drug: Triamcinolone"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow aspirate concentrate",
                              "Triamcinolone"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04990128"
                        ]
                  },
                  {
                        "Rank": 104,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1 x 10^6 MSCs",
                              "10 x 10^6 MSCs",
                              "50 x 10^6 MSCs"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: 1 x 10^6 MSCs",
                              "Biological: 10 x 10^6 MSCs",
                              "Biological: 50 x 10^6 MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1",
                              "Cohort 2",
                              "Cohort 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02351011"
                        ]
                  },
                  {
                        "Rank": 105,
                        "Acronym": [
                              "AURA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in this group will received conventional microfracture treatment as indicated for isolated cartilage defects and defined by the inclusion criteria.",
                              "Patients in this group will also receive microfracture for the treatment of isolated cartilage defects in combination with arthroscopic synovial brushing to access and release synovial MSCs into the joint space."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Microfracture",
                              "Device: Arthroscopic synovial brushing"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Intervention group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02696876"
                        ]
                  },
                  {
                        "Rank": 106,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05187936"
                        ]
                  },
                  {
                        "Rank": 107,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single dose of 500\u3395/\u33a0 of cartilage defect",
                              "conventional treatment method"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: CARTISTEM",
                              "Procedure: Microfracture"
                        ],
                        "ArmGroupLabel": [
                              "CARTISTEM",
                              "Microfracture"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01626677"
                        ]
                  },
                  {
                        "Rank": 108,
                        "Acronym": [
                              "Stemshoulder"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All the patients enrolled in the study will be treated with the bone marrow aspirate obtained with the Bone Marrow Cellution Kit."
                        ],
                        "ArmGroupInterventionName": [
                              "Device: Marrow Cellution System"
                        ],
                        "ArmGroupLabel": [
                              "Bone Marrow aspirate"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04308213"
                        ]
                  },
                  {
                        "Rank": 109,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Isolation and \"Ex-Vivo\" expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-Divisi\u00f3n de Terapias Avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Autologous MSC knee implantation"
                        ],
                        "ArmGroupLabel": [
                              "Autologous MSC knee implantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01227694"
                        ]
                  },
                  {
                        "Rank": 110,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will undergo the scheduled meniscectomy procedure. Following the procedure the investigator will make a small incision and create the marrow access channel in the proximal tibia. The experimental group will then have bone marrow harvested and BMAC will be prepared using a BMAC harvesting system. The automated centrifuge system rapidly concentrates cellular contents and growth factors in bone marrow aspirate using flow cytometry. The BMAC will be injected intra-articularly.",
                              "Subjects will undergo the same meniscectomy procedure and will also have an incision and marrow access channel made in the proximal tibia, however no bone marrow will be harvested. The control group will have a placebo injection of saline into the affected knee."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone Marrow Aspirate Concentrate",
                              "Procedure: Standard Meniscectomy",
                              "Procedure: Standard Meniscectomy"
                        ],
                        "ArmGroupLabel": [
                              "Meniscectomy with Bone Marrow Aspirate Concentrate (BMAC)",
                              "Meniscectomy with Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02582489"
                        ]
                  },
                  {
                        "Rank": 111,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients from this group will be treated with a combination of platelet-rich plasma (PRP) and hyaluronic acid (HA) prepared with the Cellular Matrix / A-CP HA medical device",
                              "Patients from this group will be treated with a well-recognized hyaluronic acid named Ostenil\u00ae Plus",
                              "Patients from this group will be treated with PRP alone, prepared with RegenKit-BCT-1"
                        ],
                        "ArmGroupInterventionName": [
                              "Device: Cellular Matrix / A-CP HA",
                              "Device: Ostenil\u00ae Plus",
                              "Device: RegenKit-BCT-1"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group",
                              "Control group 1",
                              "Control group 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02964143"
                        ]
                  },
                  {
                        "Rank": 112,
                        "Acronym": [
                              "ARTROCELL"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment with 40 millions of autologous autologous adult mesenchymal stem cells from expanded bone marrow administered intra-articularly.",
                              "Treatment with 40 millions of adult allogeneic expanded bone marrow mesenchymal stem cells administered intra-articularly.",
                              "Hyaluronic Acid 60mg/3ml administered intra-articularly."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous MSCs",
                              "Drug: Allogenic MSCs",
                              "Drug: Hyaluronic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Stromal Cells (MSC)",
                              "Allogenic Mesenchymal Stromal Cells (MSC)",
                              "Active Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05086939"
                        ]
                  },
                  {
                        "Rank": 113,
                        "Acronym": [
                              "PATTERN"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intra-articular injection of BMAC",
                              "intra-osseous and intra-articular injection of BMAC",
                              "intra-articular injection of at- SVF",
                              "intraosseous and intra-articular injection of at-SVF"
                        ],
                        "ArmGroupInterventionName": [
                              "Device: KIT BMAC AND at-SVF FIDIA",
                              "Device: KIT BMAC AND at-SVF FIDIA",
                              "Device: KIT BMAC AND at-SVF FIDIA",
                              "Device: KIT BMAC AND at-SVF FIDIA"
                        ],
                        "ArmGroupLabel": [
                              "intra-articular injection of BMAC",
                              "intra-osseous and intra-articular injection of BMAC",
                              "intra-articular injection of at- SVF",
                              "intraosseous and intra-articular injection of at-SVF"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05447767"
                        ]
                  },
                  {
                        "Rank": 114,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous bone marrow-derived stem cell transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cell Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03067870"
                        ]
                  },
                  {
                        "Rank": 115,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "SVF treatment is developed by Cellab Laboratory (Celstem\u00ae). It is approved by Andorra's Government authorities."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: SVF treatment"
                        ],
                        "ArmGroupLabel": [
                              "SVF treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04749758"
                        ]
                  },
                  {
                        "Rank": 116,
                        "Acronym": [
                              "BMAC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group will receive an injection of BMAC/PRP for treatment of OA",
                              "This group will receive an injection of cortisone for treatment of OA"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: BMAC/PRP Injection",
                              "Procedure: Cortisone Injection"
                        ],
                        "ArmGroupLabel": [
                              "BMAC/PRP Injection Group",
                              "Cortisone Injection Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03410355"
                        ]
                  },
                  {
                        "Rank": 117,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "autologous bone marrow aspirate is taken under local anesthesia to be centrifuged and the concentrate given intra articularly in knee joint",
                              "control group given analgesics only"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: autologous bone marrow aspirate concentrate by centrifugation",
                              "Procedure: autologous bone marrow aspirate concentrate by centrifugation"
                        ],
                        "ArmGroupLabel": [
                              "treatment with autologous bone marrow aspirate concentrate",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05193877"
                        ]
                  },
                  {
                        "Rank": 118,
                        "Acronym": [
                              "BMAC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in this group will receive between 1-4 ml of bone marrow aspirate concentrate (BMAC) containing mesenchymal stem cells (MSCs) obtained from their iliac crest. A small incision will be made on the anterior superior iliac spine in order to withdraw the aspirate. The aspirate will be ran through a centrifuge in order to isolate the BMAC containing MSCs. The BMAC will be injected into the ACL allograft prior to implanting into the patient.",
                              "Patients will receive a sham incision on the anterior superior iliac spine where the bone marrow aspirate is obtained in the the experimental group. This ensures proper blinding. The patient will receive the normal standard of care."
                        ],
                        "ArmGroupInterventionName": [
                              "Device: Autologous Bone Marrow Derived Mesenchymal Stem Cells",
                              "Other: Sham incision"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cell Recipient",
                              "Control Sham Incision"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04650568"
                        ]
                  },
                  {
                        "Rank": 119,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All study participants will receive intraarticular injection of the investigational biological product, PSC-01."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: PSC-01"
                        ],
                        "ArmGroupLabel": [
                              "PSC-01"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04043819"
                        ]
                  },
                  {
                        "Rank": 120,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Drug name and ingredients: CARTISTEM [allogeneic-unrelated, umbilical cord blood-derived mesenchymal stem cells, ex vivo cultured, combined with sodium hyaluronate] Dosage: Administer 0.5 mL of the combination product per cm^2 of the cartilage defect"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: CARTISTEM\u00ae"
                        ],
                        "ArmGroupLabel": [
                              "CARTISTEM\u00ae"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01733186"
                        ]
                  },
                  {
                        "Rank": 121,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: AD-SVF infusion directly into affected joints."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Liposuction with Local Anesthesia",
                              "Biological: Intra articular infusion of AD-SVF"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose-derived Stromal Vascular Fraction infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01739504"
                        ]
                  },
                  {
                        "Rank": 122,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "taking umbilical cord derived mesenchymal stem cells",
                              "taking stromal vascular fraction cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cells",
                              "Biological: Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "umbilical cord derived mesenchymal stem cells transplantation group",
                              "stromal vascular fraction cells application group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05305833"
                        ]
                  },
                  {
                        "Rank": 123,
                        "Acronym": [
                              "ERIPTO"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Protocol arm actively being studied",
                              "bone marrow aspirate concentrate only arm"
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: ERIPTO Protocol",
                              "Biological: BMAC Only"
                        ],
                        "ArmGroupLabel": [
                              "ERIPTO Protocol",
                              "BMAC only"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04222140"
                        ]
                  }
            ]
      }
}